Correction: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

In this article (Clin Cancer Res 2012;18:5499–506), which was published in the October 1, 2012, issue of Clinical Cancer Research (1), the Conflict of Interest disclosure information pertaining to Dr. Bart Barlogie was incorrect. The original disclosure read:

B. Barlogie has received research funding from Celgene, Novartis, Millennium, Centocor, Johnson and Johnson, Onyx, and ICON; is a consultant to Celgene, Millennium, and Genzyme; and has received speaking honoraria from Celgene and Millennium. He is a coinventor on patents and patent applications related to the use of GEP in cancer medicine and holds ownership interest in Signal Genetics.

This should be replaced with the following disclosure statement:

B. Barlogie has received research funding from Celgene and Millennium, is a consultant to Celgene and Millennium, and is a coinventor on patents and patent applications related to the use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC.

The authors regret this error.

Reference


Published OnlineFirst January 10, 2013. doi: 10.1158/1078-0432.CCR-12-3839
©2012 American Association for Cancer Research.
Correction: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Clin Cancer Res  Published OnlineFirst January 10, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-3839

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.